Retatrutide Phase 3 Results: What People With Type 2 Diabetes Should Know 10th June 2026 by Living Diabetes Editorial Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
CagriSema for Weight Loss and Type 2 Diabetes: What to Know 6th June 20266th April 2026 by Living Diabetes Editorial Team CagriSema combines cagrilintide and semaglutide in trials. Learn what studies show, what remains uncertain, and safety caveats.
